Sponsors (2)
The bill increases regulatory clarity and transparency to speed generic approvals and lower drug costs, but does so at the risk of constraining FDA flexibility, adding agency workload, and creating confidentiality and legal uncertainties for manufacturers.
Patients—especially uninsured people and those with chronic conditions—could get lower-cost generic drugs sooner because clearer FDA determinations and binding decisions may speed ANDA approvals and reduce litigation risk.
Generic manufacturers and small businesses face less regulatory uncertainty because FDA must issue clear determinations about inactive ingredients and must identify and quantify any differences, helping firms correct formulations faster.
Required public guidance on pH adjusters and qualitative+quantitative (Q+Q) criteria increases transparency and predictability for manufacturers and health systems.
Patients and health systems risk safety problems because binding FDA determinations that generally cannot be changed after ANDA submission could lock in approvals based on incomplete science and limit FDA's ability to respond to new safety data.
FDA workload may increase: requiring individualized determinations and formal guidance on short statutory timelines could divert agency resources and slow review of other products, delaying approvals.
Confidentiality risk: disclosing detailed formulation differences (even if authorized) could reveal proprietary information of reference drug sponsors or applicants, harming commercial interests.
Based on analysis of 2 sections of legislative text.
Introduced March 5, 2025 by Neal Patrick Dunn · Last progress March 5, 2025
Requires the Department of Health and Human Services (through FDA) to tell an applicant for a generic drug (ANDA filer) whether the proposed generic is qualitatively and quantitatively the same as the listed (brand) drug when the product is required to contain the same inactive ingredients or when FDA can rely on in vitro bioequivalence testing. If FDA finds differences, it must identify which inactive ingredients differ and any amounts that deviate. If FDA determines the product is the same, that determination generally cannot be changed after an ANDA is submitted except in narrow situations. HHS must also issue draft guidance within one year describing how FDA will make these sameness determinations, allow at least 60 days for public comment, and finalize guidance within one year after the comment period closes. The statutory disclosure rule takes effect on enactment even if guidance is not yet final.